Skip to content
BioalmanacPeptide reference
Account
Menu
Regulatory

Update

GLP-1 compounds: the gap between the trials and the vial

Semaglutide and tirzepatide have large phase 3 programmes behind them. What those programmes tested was a manufactured medicine, not a vial bought under a research label.

Semaglutide and tirzepatide are unusual on this site in having genuine clinical evidence: large randomised placebo-controlled trials with published endpoints and regulatory approval. It is reasonable to find that reassuring, and it is worth being precise about what it covers.

The trials tested a product manufactured to pharmaceutical standard: a known quantity of a known substance in each vial, made in an inspected facility, with a regulator able to act if something went wrong. That is the thing the evidence attaches to.

A research-labelled vial is a different object, and the trial results do not come with it. This is not paperwork pedantry. The evidence establishes what happens when a specific dose of a specific substance is given, and a vial of uncertain contents breaks that chain at the first link.

Both compounds are approved prescription medicines in the United States. The route that keeps the evidence attached to what you are taking is a prescription.

Compounds this concerns

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.

Read next

StackRetatrutide with MOTS-cA triple incretin agonist next to a mitochondrial peptide, on the argument that losing weight fast is easier than losing it well. The second half has never finished a human trial.ResearchRetatrutide: what the phase 3 programme does and does not settleThe largest reported weight reduction in the incretin class, from trials that are still running. What that means for a compound already being sold everywhere.ResearchNNMT inhibitors and the NAD+ story: a chain of plausible links5-Amino-1MQ is sold on a mechanism with support at every step and no human trial at any step. That combination is worth understanding on its own terms.